Dan Skovronsky
Dr. Dan Skovronsky is the Chief Scientific Officer at Eli Lilly, where he has played a pivotal role in the development of innovative treatments for diabetes and obesity. Recently, he announced promising results from clinical trials of orforglipron, an experimental GLP-1 pill that significantly helped participants with type 2 diabetes lose weight and lower blood sugar levels.
Not in the pool (under ¢1).
Recent news mentions
Eli Lilly's chief scientific officer Dan Skovronsky mentioned that the new medication could be a primary treatment for both type 2 diabetes and obesity.
uus tablett jätab süstid ajalukku
Estonia· 2025-12-01
Dr. Dan Skovronsky, Lilly’s chief scientific officer, said in April that his company has begun mass-producing orforglipron pills after previous promising results.
New GLP-1 pill for weight loss may be closer to reality as drugmaker Eli Lilly says it will file for regulatory approval
United States· 2025-08-26Dr. Dan Skovronsky, Lilly’s chief scientific officer, expressed confidence in the trial results before they were released.
Eli Lilly says experimental GLP-1 pill helped people with diabetes lose weight and lower blood sugarUnited States· 2025-04-18
